Filing Flows › Taysha Gene Therapies (TSHA) › Q4 2024
Taysha Gene Therapies (TSHA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 26, 2025
Taysha Gene Therapies (TSHA) reported revenue of $2.0M for the fourth quarter 2024 (Q4 2024), -44% from a year earlier and +13% from the quarter before. Operating margin was -985.8%, net loss $18.8M (929.0% of revenue).
Taysha Gene Therapies, Q4 2024: revenue $2.0M (-44% year over year), operating margin -985.8%, net loss $18.8M, operating cash flow −$18.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.0M | +13% | -44% |
| Operating profit | −$19.9M | — | — |
| Net earnings | −$18.8M | — | — |
| Operating cash flow | −$18.3M | — | — |
What changed
Revenue was $2.0M in Q4 2024, down 44% year over year and up 13% from the previous quarter.
Operating costs exceeded revenue by $19.9M, an operating margin of -985.8%. Total costs grew 11% against a revenue fall of 44%. The fastest-growing cost line was Research & development (+21%). The quarter ended with a net loss of $18.8M, narrower than the previous quarter's $25.5M loss.
Operating cash flow was −$18.3M. Non-cash charges added back $304K of depreciation and $3.2M of share-based compensation. Working capital and other items used $3.0M. Capital expenditures of −$2K exceeded it, leaving free cash flow of −$18.3M.
Questions
What was Taysha Gene Therapies' revenue in the fourth quarter 2024?
Taysha Gene Therapies (TSHA) reported revenue of $2.0M for the fourth quarter 2024 (Q4 2024), -44% from a year earlier and +13% from the quarter before.
Was Taysha Gene Therapies profitable in the fourth quarter 2024?
Operating loss was $19.9M (-985.8% of revenue) and net loss $18.8M.